ASMBS 2026
Serious CKD risks cut by bariatric surgery
Clinical takeaway: The findings strengthen the case for considering bariatric surgery earlier in patients with obesity and chronic kidney disease before kidney function deteriorates further.
Obesity is a major driver of chronic kidney disease (CKD) progression, but bariatric surgery is rarely used as part of CKD management. This real-world analysis examined whether surgery alters the disease trajectory in patients with obesity and CKD, looking at kidney, cardiovascular, and mortality outcomes over five years.
Surgery was tied to substantially better outcomes across every endpoint examined. Patients who underwent bariatric surgery were about half as likely to progress to end-stage kidney disease (5.9% vs. 11.9%) and roughly 60% less likely to require dialysis (4.1% vs. 9.0%). They were more than twice as likely to receive a kidney transplant (4.6% vs. 2.2%). Major cardiovascular events such as heart attack and stroke occurred at nearly half the rate (15.5% vs. 27.7%), and mortality fell from 16% to 5%, a reduction of more than 75%.
The pattern points to surgery's effect on the metabolic drivers of CKD rather than weight loss alone. Obesity, type 2 diabetes, and hypertension are the dominant risk factors for kidney disease progression, and bariatric surgery improves all three more durably than medical therapy. The improved transplant access is also notable: many patients with obesity are excluded from transplant lists until they reach a target body mass index, and surgery may open that pathway for patients who would otherwise remain on dialysis.
The analysis drew on the TriNetX Research Network electronic health record database, covering more than 8,900 patients with obesity and CKD treated between 2010 and 2020. Patients who underwent sleeve gastrectomy or Roux-en-Y gastric bypass were compared with matched non-surgical patients of similar health status. Findings were presented in abstract form and have not yet undergone full peer review.
CKD affects roughly 1 in 7 U.S. adults and is a leading cause of death. The findings add to a growing body of evidence that bariatric surgery's benefits extend beyond weight loss to organ-level disease modification, though prospective trials would be needed to confirm causality and define which CKD patients benefit most.
"These findings show metabolic and bariatric surgery doesn't just treat obesity, it fundamentally alters the course of chronic kidney disease and should be considered earlier in the disease process," said lead author Jerry Dang, MD, PhD, associate professor of surgery at Cleveland Clinic Lerner College of Medicine of Case Western Reserve University. "With earlier intervention, we see slower disease progression, fewer patients advancing to kidney failure, better cardiovascular outcomes and greater access to life-saving transplants."
Source: Kachornvitaya P. ASMBS 2026 Annual Scientific Meeting Abstract 4520. Long-term renal and survival outcomes in patients with obesity and chronic kidney disease following metabolic and bariatric surgery: a TriNetX cohort study